A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT03298542
- Locations
- 🇺🇸
UC Denver-Colorado Barbara Davis Center, University of Colorado SOM Pediatric Endocrinology, Aurora, Colorado, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇸🇪Lund University Hospital/Skåne, Lund/Malmo, Sweden
A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03298906
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function
Phase 1
Withdrawn
- Conditions
- Hepatic Impairment
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03277755
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Dara SCDrug: Dara IV
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 522
- Registration Number
- NCT03277105
- Locations
- 🇮🇹
Azienda USL di Piacenza, Piacenza, Italy
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, Australia
A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference)Drug: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT03274297
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [18F]JNJ-64511070
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT03270579
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT03267576
- Locations
- 🇲🇽
Investigación Clínica Especializada, Guadalajara, Mexico
🇲🇽Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico
🇲🇽Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
Phase 2
Completed
- Conditions
- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
- Interventions
- Drug: JNJ-64179375 0.3 mg/kgDrug: JNJ-64179375 0.6 mg/kgDrug: JNJ-64179375 1.2 mg/kgDrug: JNJ-64179375 (Dose to be Determined)Drug: JNJ-64179375 A mg/kgDrug: JNJ-64179375 B mg/kgDrug: JNJ-64179375 C mg/kgDrug: JNJ-64179375 D mg/kgDrug: Placebo JNJ-64179375Drug: Apixaban placeboDrug: Apixaban 2.5 mg
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 308
- Registration Number
- NCT03251482
- Locations
- 🇺🇦
Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, Ukraine
🇺🇸Denver Metro Orthopedics, PC, Englewood, Colorado, United States
🇧🇪ZNA Jan Palfijn, Merksem, Belgium
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)Drug: CanagliflozinDrug: Glucagon-Like Peptide-1 Agonist (GLP-1)Drug: EmpagliflozinDrug: Thiazolidinedione (TZD)Drug: DapagliflozinDrug: SulfonylureasDrug: Insulin
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25358
- Registration Number
- NCT03249506
- Locations
- 🇺🇸
Health ResearchTx, LLC, Trevose, Pennsylvania, United States
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Early Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: [18F]MNI-1020
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT03239561
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath